NHI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
National Health Investors Inc (NHI) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has stable dividends and positive revenue growth, the technical indicators and options data suggest a lack of strong upward momentum. Additionally, recent analyst ratings and price target adjustments do not indicate significant upside potential. Given the user's preference for long-term investment, it is better to wait for a more favorable entry point or stronger positive catalysts.
The MACD histogram is negative and expanding, indicating bearish momentum. RSI is neutral at 34.287, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 84.441), but there is no strong indication of a rebound. The stock's short-term trend suggests a 60% chance of a -1.26% decline in the next day and a -8.03% decline in the next month.
Stable dividend yield of 4%, with a quarterly dividend of $0.92 per share.
Revenue growth of 23.4% YoY in Q4 2025, exceeding market forecasts.
Positive full-year normalized FFO growth of 10.6%.
Net income and EPS declined YoY in Q4 2025 (-11.8% and -15.79%, respectively).
Gross margin dropped to 75.43%, down 10.35% YoY.
Analysts have downgraded the stock recently, with Deutsche Bank moving it to Hold and Cantor Fitzgerald lowering the price target.
The stock's short-term trend indicates potential declines in the next month.
In Q4 2025, revenue increased by 23.4% YoY to $105.8 million, exceeding forecasts. However, net income dropped by 11.8% YoY to $38.1 million, and EPS declined by 15.79% YoY to $0.8. Gross margin also fell to 75.43%, down 10.35% YoY. Despite strong revenue growth, declining profitability metrics raise concerns.
Recent analyst ratings show mixed sentiment. Deutsche Bank downgraded the stock to Hold with an $85 price target, while Cantor Fitzgerald lowered the price target to $85 but maintained an Overweight rating. Truist raised the price target to $83 and kept a Buy rating. Analysts highlight stable fundamentals and a strong dividend yield but note underperformance in the senior housing portfolio and macroeconomic challenges.
